 | David SugrueDavid Sugrue, B.S., is a 2015 Pharm.D. candidate; Robin Bogner, M.S., Ph.D., is Associate Professor of Pharmaceutics; and Megan J. Ehret, Pharm.D., M.S., BCPP, is Associate ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
David Sugrue:Expert Impact
Concepts for whichDavid Sugruehas direct influence:Hyperactivity disorder,Deficit hyperactivity,Disorder hyperactivity,Disorder adhd,Methylphenidate tablets,Nervous stimulants,Stimulants child,Humans methylphenidate.
David Sugrue:KOL impact
Concepts related to the work of other authors for whichfor which David Sugrue has influence:Excessive blinking,Hyperactivity disorder,Laboratory classroom setting,Dopamine compartmentalization,Mpd adulthood,Adults adhd,Young brain.
KOL Resume for David Sugrue
| Year | |
|---|---|
| 2014 | David Sugrue, B.S., is a 2015 Pharm.D. candidate; Robin Bogner, M.S., Ph.D., is Associate Professor of Pharmaceutics; and Megan J. Ehret, Pharm.D., M.S., BCPP, is Associate Professor of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs |
| Concept | World rank |
|---|---|
| methylphenidate tablets | #98 |
Prominent publications by David Sugrue
Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder
[ PUBLICATION ]
PURPOSE: Current literature on the safety and efficacy of various intermediate- and long-acting preparations of methylphenidate and dexmethylphenidate for pediatric attention-deficit/hyperactivity disorder (ADHD) is reviewed.
SUMMARY: The efficacy of methylphenidate in controlling ADHD symptoms is firmly established. Given the drug's relatively short half-life in pediatric patients (about 2.5 hours), a number of intermediate- and long-acting products have been developed; these ...
| Known for Hyperactivity Disorder | Adhd Symptoms | Attention Deficit | Extended Release | Methylphenidate Tablets |
